http://www.learnjapanesesite.com
Pipeline and Commercial Insight: Obesity - the 11 billion market that never was
The obesity market is easily characterized as attractive, featuring a booming patient potential needing long term therapy, but repeated product withdrawals and failed pipeline candidates highlight the reality of increasingly cautious regulatory bodies, reluctant payers, and a clinical community that puts more stock in diet and exercise: $513.7m sales in 2008 fall far short of analyst predictions. (
http://www.bharatbook.com/detail.asp?id=129379 AND rt=Pipeline-and-Commercial-Insight-Obesity-the-11-billion-market-that-never-was.html )
Scope of this research
Defining the key clinical characteristics of the obesity sector that present a unique commercial challenge
Translation of critical clinical and regulatory issues into pertinent practical considerations for both incumbent players and new market entrants
Clinical and commercial analysis of existing and late stage products targeting the sector, qualified by key opinion leader interviews
Seven major market forecasts for key products to 2018
Research and analysis highlights
The 125 million obese adults in 2008 across the US, Japan, France, Germany, Italy, Spain and UK will grow to at least 143 million by 2018. If just 25% of these adults were treated for one year with a dollar per day product, achieving 80% compliance rates, market potential would rise from $8.Obesityhealthmedical
